Novartis AGNN

Novartis AG

117.70USDR
+0.24+0.20%
At close at Jul 25, 23:57 GMT
USD
No trades
See on Supercharts

Key facts today


Novartis faces challenges in the pharmaceutical sector, with the Stoxx Europe Pharmaceuticals index down over 20% since September, contrasting with a 10% rise in broader European stocks.
Analyze the impactAnalyze the impact
Next report date
October 28
Report period
Q3 2025
EPS estimate
2.25 USD
Revenue estimate
‪13.77 B‬ USD
Market capitalization
‪223.31 B‬USD
6.95USD
‪11.93 B‬USD
‪50.29 B‬USD
‪1.90 B‬
Beta (1Y)
0.28

About NOVARTIS N


CEO
Vasant Narasimhan
Headquarters
Basel
Founded
1996
FIGI
BBG000LYF3S8
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Performance
‪20.0%‬
‪22.5%‬
‪25.0%‬
‪27.5%‬
‪30.0%‬
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Debt level and coverage
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Oct 28, 2025
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
‪2.80‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US66989HAS7
NOVARTIS CAP 20/50
Yield to maturity
6.82%
Maturity date
Aug 14, 2050
XPND
NOVARTIS CAPITAL 15/45
Yield to maturity
6.00%
Maturity date
Nov 20, 2045
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.99%
Maturity date
Sep 21, 2042
US66989HAH1
NOVARTIS CAPITAL 14/44
Yield to maturity
5.81%
Maturity date
May 6, 2044
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.77%
Maturity date
Sep 18, 2054
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
4.87%
Maturity date
Sep 18, 2034
XPNC
NOVARTIS CAPITAL 15/25
Yield to maturity
4.69%
Maturity date
Nov 20, 2025
US66989HAR9
NOVARTIS CAP 20/30
Yield to maturity
4.49%
Maturity date
Aug 14, 2030
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031
Yield to maturity
4.42%
Maturity date
Sep 18, 2031
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029
Yield to maturity
4.18%
Maturity date
Sep 18, 2029
US66989HAN8
NOVARTIS CAPITAL 17/27
Yield to maturity
4.15%
Maturity date
May 17, 2027

See all NVS bonds